Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Posts Tagged ‘Sound Shore’s Q1 2019 Investor Letter’

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research

Alexion Pharmaceuticals, Inc. (ALXN): Sound Shore Says the Pharmaceutical Company is Driving Innovation

Sound Shore posted 20 year annualized returns of 7.30% and 7.51% for its Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX), respectively......(read more)

Sensata Technologies Holding plc (ST): Sound Shore Believes It Has a Good Risk/Reward Profile

As per its recently released Q1 2019 Investor Letter, Sound Shore returned 11.88% and 11.91% for its Sound Shore Fund Investor Class (SSHFX) and Institutional......(read more)